KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Adaptive Biotechnologies (ADPT) EBITDA (2018 - 2025)

Adaptive Biotechnologies (ADPT) has disclosed EBITDA for 8 consecutive years, with $3.0 million as the latest value for Q4 2025.

  • Quarterly EBITDA rose 113.6% to $3.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$987000.0 through Dec 2025, up 98.56% year-over-year, with the annual reading at $15.2 million for FY2025, 136.85% up from the prior year.
  • EBITDA hit $3.0 million in Q4 2025 for Adaptive Biotechnologies, down from $23.7 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $78.9 million in Q4 2023 to a low of -$63.1 million in Q1 2022.
  • Historically, EBITDA has averaged -$24.6 million across 5 years, with a median of -$29.7 million in 2023.
  • Biggest five-year swings in EBITDA: tumbled 127.95% in 2024 and later surged 309.2% in 2025.
  • Year by year, EBITDA stood at -$61.6 million in 2021, then skyrocketed by 36.38% to -$39.2 million in 2022, then skyrocketed by 301.31% to $78.9 million in 2023, then crashed by 127.95% to -$22.1 million in 2024, then soared by 113.6% to $3.0 million in 2025.
  • Business Quant data shows EBITDA for ADPT at $3.0 million in Q4 2025, $23.7 million in Q3 2025, and $1.9 million in Q2 2025.